New Jersey is currently home to 1657 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study Investigating Lu AG22515 in Healthy Adults
NCT05303246
Recruiting
The main goal of this study is to learn more about the safety of a drug called Lu AG22515. During the trial, healthy adult participants will receive a single dose of Lu AG22515 or a placebo (normal saline solution).
Gender:
All
Ages:
Between 19 years and 60 years
Trial Updated:
03/21/2022
Locations: Frontage Clinical Services, Inc., Secaucus, New Jersey
Conditions: Healthy Participants
Register for Updates
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT05211856
Recruiting
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
01/14/2022
Locations: Research Site, Brick, New Jersey
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Early Feasibility Study of the Cardiac Implants Percutaneous Ring Annuloplasty System
NCT04890821
Recruiting
An early feasibility study to evaluate the safety and performance of 1) the transcatheter delivery and implantation of the Cardiac Implants (CI) annuloplasty ring and 2) the adjustment of the ring approximately 90 days following implantation in patients suffering from ≥ moderate functional tricuspid regurgitation (FTR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2021
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Tricuspid Regurgitation Functional
Register for Updates
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
NCT03906617
Recruiting
This study will assess analgesia after robotic lung surgery. Subjects will be randomized to receive wound infiltration and intercostal nerve block with either liposomal bupivacaine or bupivacaine/epinephrine + dexamethasone. Liposomal bupivacaine is a newer local anesthetic product and has not been compared to a combination of bupivacaine/epinephrine + dexamethasone in the context of pain control after robotic lung surgery.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
11/11/2021
Locations: Cooper University Hospital, Camden, New Jersey
Conditions: Robotic Lung Surgery
Register for Updates
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
NCT03509961
Recruiting
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regime... Read More
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
08/20/2021
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: B-cell Acute Lymphoblastic Leukemia
Register for Updates
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy. (LIMBER-213)
NCT04821791
Recruiting
This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2021
Locations: New Jersey Hematology Oncology Associates Llc, Brick, New Jersey
Conditions: Myelofibrosis, Polycythemia Vera, Thrombocythemia
Register for Updates
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04816578
Recruiting
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/24/2021
Locations: New Jersey Hematology Oncology Associates Llc, Brick, New Jersey
Conditions: Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Register for Updates
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
NCT04519099
Recruiting
To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 mg/d compared with placebo in prevention of relapse in patients with schizophrenia To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
08/17/2020
Locations: Hassman Research Institute, Berlin, New Jersey
Conditions: Schizophrenia
Register for Updates
Taltz in Combination With Enstilar for Psoriasis
NCT04372277
Recruiting
Enstilar in combination with Taltz for plaque psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2020
Locations: Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey
Conditions: Psoriasis
Register for Updates
Duobrii in Combination With Biologics
NCT04119102
Recruiting
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2020
Locations: Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey
Conditions: Psoriasis
Register for Updates
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
NCT04347473
Recruiting
Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/13/2020
Locations: Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey
Conditions: Psoriasis
Register for Updates
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
NCT03827876
Recruiting
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2019
Locations: Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey
Conditions: Psoriasis
Register for Updates